Antibiotic Treatment and Resistance
Pneumonia caused by Mycoplasma pneumoniae is routinely treated with antibiotics, although the disease is usually self-limiting. The disease is treated with macrolide, tetracycline, or fluoroquinolone classes of antibiotics. All mycoplasmas lack a cell wall and, therefore, all are inherently resistant to beta-lactam antibiotics (e.g., penicillin).
Macrolides (e.g., azithromycin) are generally considered the treatment of choice for both children and adults. In addition to macrolides, fluoroquinolones are recommended for the treatment of adults and tetracyclines (e.g., doxycycline) can be used for older children and adults. Neither fluoroquinolones nor tetracyclines are considered acceptable for young children under normal circumstances. Fluoroquinolones are bactericidal (macrolides and tetracyclines are primarily bacteriostatic), but they exhibit a minimum inhibitory concentration that is significantly higher than macrolides.
Physicians should practice prudent use of macrolide drugs due to the emergence of macrolide-resistant strains of M. pneumoniae.
Resistance to macrolides has been emerging in M. pneumoniae since 2000. This issue is especially troubling in Asia, where resistance rates have been shown to be as high as 90%, but macrolide resistance has also been reported in the United States and Europe. Current data suggest that the prevalence of macrolide resistance in M. pneumoniae is probably rising in the United States, possibly due to increased use of azithromycin in recent years to treat a number of illnesses.
Some studies have cited that patients infected with macrolide-resistant strains of M. pneumoniae may respond less well to macrolide antibiotics, with fever and persistent cough for a longer duration than patients infected with macrolide-sensitive strains; however, these data are not definitive. In some patients with macrolide-resistant strains, improvement in symptoms occurred after changing to doxycycline or a fluoroquinolone.
Enough is not yet known about the extent of macrolide-resistance and its clinical implications in the United States to alter prescribing guidance for pneumonia caused by M. pneumoniae infections.
- Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, Zhang JZ, Liu YM, Zhang YY, Wang H, Wang C. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010;51:189–94.
- Cardinale F, Chironna M, Chinellato I, Principi N, Esposito S. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol. 2013;51:723–4.
- Hicks LA, Taylor TH Jr, Hunkler RD. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med. 2013;368:1461–2.
- Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, Ebihara T, Ubukata K, Sato Y, Akita H, Sunakawa K, Iwata S. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15:380–3.
- Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, Suzuki I, Andoh T, Kenri T, Sasaki Y, Horino A, Shintani M, Arakawa Y, Sasaki T. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother. 2004;48:4624–30.
- Morozumi M, Iwata S, Hasegawa K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008;52:348–50.
- Okazaki N, Narita M, Yamada S, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001;45:617–20.
- Pereyre S, Charron A, Renaudin H, et al. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol. 2007;45:3534–9.
- Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother. 2013;68:506–11.
- Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006;50:709–12.
- Page last reviewed: March 15, 2016
- Page last updated: March 15, 2016
- Content source: